OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. - Wikidata - wikimedia - TriplyDB

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

http://www.wikidata.org/entity/Q34804892

about

Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Current and potential urological applications of botulinum toxin A.Use of botulinum toxin for voiding dysfunction.Clinical practice of BOTOX(®) treatment for overactive bladder syndrome in Sweden: an assessment of resource use and external validity.Safety issues associated with using medication to treat overactive bladder.Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.Can botox improve night-time overactive bladder symptoms in women?Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection.Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.

P2860

Q26749613-FD494FF0-81BA-47AD-BFD7-218BE293796D Q26770415-FCB1CF93-A709-4B1E-92DB-61A153BCE97E Q35908570-5563707C-0E0D-419D-AA66-0AE8D86300A9 Q36615109-53C1A9B6-40AC-4CA1-BBE7-C6EB27F2EDE5 Q37514596-B88A3620-6E0E-42D9-9D50-D4E9CB069C4B Q38564108-9581F033-4421-4122-8F33-ADB0FFC100C4 Q38679555-3BE00C34-F9A8-49D8-823B-2D952188CB55 Q39415488-8D21D348-70F6-4EBB-90BB-CE95E6AEF522 Q40058585-8229A327-A82E-436D-8A3D-00B82B4B1B1B Q40118662-89F0C0AB-9E94-4435-AB28-6E9B02B748CB Q40887604-3A2B2BC2-75C1-4F6D-A4E4-E1B0A7C1F9E5 Q40989355-1A36B7BC-4EE8-409F-9FA7-0B6B36E323A8 Q45788137-33DC98D8-5963-4EEE-AF28-CB73A397333A Q46367789-86210EE4-E2C4-4FA3-8818-29CAA8EC7BB8 Q47433658-4E61C347-78AE-4631-BDD3-92FC41DDD28D Q50890026-6AAFC38C-03A4-4DFA-9C1F-93C033002533

P2860

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

http://www.wikidata.org/entity/Q34804892

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@ast

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@en

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@nl

type

label

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@ast

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@en

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@nl

prefLabel

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@ast

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@en

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@nl

P1433

Q34804892-61685E2D-CE18-47B9-8613-B88585B4A2D7

P1476

Q34804892-7A00CF99-7699-469F-B7B0-9B800067C6BD

P2093

Q34804892-32BB8D71-5ABA-4817-891B-109046F3FC70

Q34804892-37662BB3-F6E3-40EB-9D3F-379F50B66C25

Q34804892-561A51C5-1C34-4A08-A713-A0251013423A

Q34804892-8FDFB015-2FAD-4347-8736-A15C9C20509A

Q34804892-DDC288B2-00E6-41D6-87C3-2CE3717910A0

Q34804892-F8B61571-0A4B-44C0-AEE8-7C0D626F4291

P2860

Q34804892-0C2B59F6-8ED2-41EB-A040-668A2B496DCC

Q34804892-178E1296-6D26-460E-8C12-F0BD66526DD8

Q34804892-1D1850F5-6C84-4AFB-8259-C5C3E8CFBFE9

Q34804892-2CDCCD23-E6B1-4005-A3DB-07C149F3141E

Q34804892-37F4FB14-37A6-4C33-B4D0-71E22F6E6406

Q34804892-38161309-2215-4361-82F2-F7BA9B04A420

Q34804892-3905E542-B8CC-4D60-A90D-171A883E1590

Q34804892-3B0C9488-8601-44CE-9207-79C5456500B6

Q34804892-42C744CE-B67B-4DF0-856E-E3BA2925EBA8

Q34804892-44EEBB0A-21EE-403F-93F1-F8EA35D8CCAB

P304

Q34804892-A412B0E4-C7D6-4E96-A8C6-37A3B0FFF044

P31

Q34804892-34B32ACF-AB8D-4B4C-B51F-840EFB96BA46

P356

Q34804892-ADF59494-82E2-489E-A19B-B3F5F7B3267A

P433

Q34804892-7DCB6D9A-BC8F-4830-9667-5729533E2CBE

P478

Q34804892-5831137C-5D15-47DA-9F9B-C7A6560A1F62

P50

Q34804892-F7D3349C-29C2-422F-A824-05461D7ED77E

P577

Q34804892-FACBE7C1-0BE8-477A-A842-90F7F23837C4

P5875

Q34804892-003BCCC5-05A7-43DA-A08D-4E54BA379EDC

P698

Q34804892-652155FD-BCDE-416D-AC01-CF2E5D237FA1

P932

Q34804892-119EDDE7-E8B3-4D4C-8915-04DC723461A5

P356

P1433

International Journal of Clinical Practice

P1476

OnabotulinumtoxinA 100U provid ...... agement of overactive bladder.

@en

P2093

C Nardo

http://www.w3.org/2001/XMLSchema#string

J Zhou

http://www.w3.org/2001/XMLSchema#string

K-D Sievert

http://www.w3.org/2001/XMLSchema#string

M Joshi

http://www.w3.org/2001/XMLSchema#string

S Herschorn

http://www.w3.org/2001/XMLSchema#string

V W Nitti

http://www.w3.org/2001/XMLSchema#string

P2860

Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains.

Prevalence and burden of overactive bladder in the United States.

Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.

Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.

Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.

Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS.

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.

P304

1246-1256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12443

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Christopher R Chapple

P577

2014-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261804626

http://www.w3.org/2001/XMLSchema#string

P698

24754838

http://www.w3.org/2001/XMLSchema#string

P932

4282287

http://www.w3.org/2001/XMLSchema#string